A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): Study protocol for a randomized double-blind controlled trial
Data de publicação2011-02-24
Direito de acesso
MetadadosExibir registro completo
Background: Cardiovascular disease is the leading cause of death in Brazil, and hypertension is its major risk factor. The benefit of its drug treatment to prevent major cardiovascular events was consistently demonstrated. Angiotensin-receptor blockers (ARB) have been the preferential drugs in the management of hypertension worldwide, despite the absence of any consistent evidence of advantage over older agents, and the concern that they may be associated with lower renal protection and risk for cancer. Diuretics are as efficacious as other agents, are well tolerated, have longer duration of action and low cost, but have been scarcely compared with ARBs. A study comparing diuretic and ARB is therefore warranted.Methods/design: This is a randomized, double-blind, clinical trial, comparing the association of chlorthalidone and amiloride with losartan as first drug option in patients aged 30 to 70 years, with stage I hypertension. The primary outcomes will be variation of blood pressure by time, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new subclinical atherosclerosis and sudden death. The study will last 18 months. The sample size will be of 1200 participants for group in order to confer enough power to test for all primary outcomes. The project was approved by the Ethics committee of each participating institution.Discussion: The putative pleiotropic effects of ARB agents, particularly renal protection, have been disputed, and they have been scarcely compared with diuretics in large clinical trials, despite that they have been at least as efficacious as newer agents in managing hypertension. Even if the null hypothesis is not rejected, the information will be useful for health care policy to treat hypertension in Brazil. Clinical trials registration number: ClinicalTrials.gov: NCT00971165. © 2011 Fuchs et al; licensee BioMed Central Ltd.
Como citar este documento
Este item aparece nas seguintes coleções
Exibindo os itens relacionados pelo título, autor e palavra-chave.
Therapeutic response of benzodiazepine, orphenadrine citrate and occlusal splint association in TMD pain Rizzatti-Barbosa, Célia M.; Martinelli, Denise A.; Ambrosano, Gláucia M. B.; De Albergaria-Barbosa, José R. (Cranio, 2003) [Artigo]Loss of function, muscle inflammation, and pain are some of the signs and symptoms of temporomandibular dysfunction (TMD). Pharmacological strategies to minimize the clinical manifestation of these disorders often focus ...
Influence of preventive dental treatment on mutans streptococci counts in patients undergoing head and neck radiotherapy Meca, Lívia Buzati; Souza, Fátima Regina Nunes de; Tanimoto, Helio Massaioshi; Castro, Alvimar Lima de ; Gaetti-Jardim Júnior, Elerson (Journal of applied oral science : revista FOB, 2009) [Artigo]The aim of this study was to evaluate the influence of chlorhexidine gluconate, sodium fluoride and sodium iodine on mutans streptococci counts in saliva of irradiated patients. Forty-five patients were separated into three ...
Fluoride intake from regular and low fluoride dentifrices by 2-3-year-old children: Influence of the dentifrice flavor Moraes, Samanta Mascarenhas; Pessan, Juliano Pelim ; Ramires, Irene; Buzalaf, Marília Afonso Rabelo (Brazilian Oral Research, 2007) [Artigo]This study evaluated the fluoride intake from dentifrices with different fluoride concentrations ([F]) by children aged 24-36 months, as well as the influence of the dentifrice flavor in the amount of fluoride ingested ...